Xerophthalmia (Dry Eyes)

What is Xerophthalmia (dry eyes)?

Xerophthalmia, commonly known as dry eye disease (DED), is a chronic, multifactorial condition in which the eyes do not produce enough tears or the tear film is of poor quality. The result is an unstable ocular surface that leads to irritation, visual disturbance, and, if untreated, damage to the cornea and conjunctiva. Xerophthalmia is one of the most frequent reasons patients seek ophthalmic care, affecting an estimated 5‑30 % of the adult population worldwide, with higher prevalence in older adults and women.^[1][2]

Common Causes

Dry eye is usually the result of an interplay between environmental, systemic, and ocular factors. Below are the most frequent contributors:

• Age‑related tear film changes – Meibomian gland function declines after age 40, reducing the lipid layer that prevents evaporation.
• Hormonal influences – Androgen deficiency, menopause, and hormonal birth control can diminish tear production.
• Contact lens wear – Lenses disturb the tear film and may cause mechanical irritation.
• Medications – Antihistamines, decongestants, antidepressants, beta‑blockers, and isotretinoin are known to lower tear output.
• Environmental exposure – Low humidity, wind, air conditioning, and prolonged screen time increase tear evaporation.
• Autoimmune diseases – Sjögren’s syndrome, rheumatoid arthritis, and lupus attack lacrimal glands.
• Eye surgeries – LASIK, cataract extraction, and ptosis repair can temporarily disrupt corneal nerves and reduce reflex tearing.
• Blepharitis & meibomian gland dysfunction (MGD) – Inflammation of the eyelid margins blocks lipid secretion.
• Refractive errors & uncorrected vision problems – Inadequate correction forces the eye to work harder, promoting tear evaporation.
• Systemic conditions – Diabetes, thyroid disease, and vitamin A deficiency can impair tear production.

Associated Symptoms

Patients with xerophthalmia often notice a constellation of sensations and signs, which may vary from mild discomfort to severe pain:

• Grittiness or “foreign body” sensation
• Burning, stinging, or itching
• Redness (conjunctival hyperemia)
• Blurry vision that improves with blinking
• Excessive tearing (reflex tearing) as the eye tries to compensate
• Stringy discharge or mucous buildup
• Sensitivity to light (photophobia)
• Difficulty wearing contact lenses
• Feeling of eye fatigue, especially after screen use

When to See a Doctor

Most dry‑eye cases can be managed with over‑the‑counter lubricants, but you should schedule an eye‑care appointment if you notice any of the following:

• Pain that is moderate to severe or not relieved by artificial tears.
• Persistent redness lasting more than a few days.
• Fluctuating or decreasing vision that does not improve with blinking.
• Signs of infection such as purulent discharge, swelling, or fever.
• History of autoimmune disease, recent eye surgery, or systemic medication changes.
• Symptoms that interfere with daily activities (reading, driving, working on a computer).

Diagnosis

Ophthalmologists and optometrists use a structured approach to confirm dry‑eye disease and determine its type (aqueous‑deficient vs. evaporative). Common evaluation steps include:

1. Patient History

Questions about symptom duration, environmental exposures, medication use, systemic illnesses, and lifestyle (screen time, contact lens wear).

2. Slit‑lamp Examination

Allows a detailed look at the eyelid margins, meibomian glands, conjunctiva, and cornea for signs such as punctate epithelial erosions or blepharitis.

3. Tear Film Tests

• Schirmer I Test – Filter paper strip measures basal tear production (≤5 mm/5 min suggests aqueous deficiency).
• Tear Break‑Up Time (TBUT) – Fluorescein dye observes how quickly the tear film destabilizes (≤10 seconds is abnormal).
• Osmolarity Test – Elevated tear osmolarity (>308 mOsm/L) is a hallmark of dry eye.
• Lipid Layer Interferometry – Specialized devices assess the thickness of the lipid layer.

4. Imaging & Advanced Tests

Meibography (infrared imaging) visualizes gland dropout, while confocal microscopy can detect corneal nerve changes.

5. Grading Scales

The DEWS II (Dry Eye Workshop) grading system integrates symptoms (e.g., OSDI questionnaire) with clinical findings to categorize severity.

Treatment Options

Management is individualized based on cause, severity, and patient preferences. A step‑wise regimen is often recommended:

1. Lifestyle Modifications & Home Care

• Follow the 20‑20‑20 rule when using screens: every 20 minutes, look at something 20 feet away for at least 20 seconds.
• Increase indoor humidity (humidifiers) and avoid direct drafts.
• Wear wrap‑around sunglasses outdoors to reduce wind‑evaporation.
• Stay well‑hydrated and limit caffeine/alcohol, which can dehydrate the ocular surface.
• Warm compresses (5–10 minutes) followed by gentle lid massage can unblock meibomian glands.
• Consider omega‑3 fatty acid supplementation (1–2 g EPA/DHA daily) as it may improve meibomian gland secretions.^[3]

2. Over‑the‑Counter (OTC) Lubricants

• Artificial tears – Preserve or restore tear volume; choose preservative‑free drops for frequent use.
• Ointments/gels – Thicker formulations for overnight relief.

3. Prescription Medications

• Cyclosporine A 0.05 % ophthalmic emulsion (Restasis) – Reduces inflammation and increases tear production; onset may take 3‑6 months.
• Lifitegrast 5 % (Xiidra) – An antagonist of LFA‑1/ICAM‑1 interaction; improves symptoms within weeks.
• Topical steroids (short‑course) – For acute inflammation, used under close supervision.
• Tetracycline or doxycycline – Oral antibiotics at sub‑antimicrobial doses modify meibomian gland secretions and reduce inflammation.
• Autologous serum eye drops – For severe cases; contains growth factors and vitamins similar to natural tears.

4. Procedural Interventions

• Punctal plugs – Silicone or collagen devices inserted into tear ducts to retain tears.
• Meibomian gland expression (MGX) – In‑office manual or thermal expression to clear blocked glands.
• Intense pulsed light (IPL) therapy – Reduces inflammation of eyelid skin and improves gland function.
• Thermal pulsation (e.g., LipiFlow) – Delivers controlled heat and massage to melt obstructive meibum.
• Amniotic membrane transplantation – Reserved for severe ocular surface disease.

5. Emerging Therapies

Research is evaluating novel agents such as recombinant human lubricin, nanomicellar cyclosporine formulations, and neurostimulation devices that enhance natural tear reflexes.

Prevention Tips

While some risk factors (age, genetics) cannot be altered, many practical steps can reduce the likelihood of developing xerophthalmia or keep it from worsening:

• Maintain a balanced diet rich in omega‑3 fatty acids (fatty fish, flaxseed, walnuts).
• Take regular breaks during prolonged visual tasks; blink consciously.
• Avoid smoking and second‑hand smoke, which irritate the ocular surface.
• Use preservative‑free artificial tears before and after contact lens insertion.
• Replace older contact lenses and follow proper hygiene protocols.
• Schedule routine eye examinations, especially if you have systemic autoimmune diseases.
• Review medication lists with your physician; alternatives may be available for drugs that cause dryness.

Emergency Warning Signs

Key Take‑aways

Dry eye disease is a common, often chronic condition that can significantly impact quality of life. Understanding its causes, recognizing associated symptoms, and seeking timely evaluation are essential. Most patients achieve relief through a combination of lifestyle changes, lubricating eye drops, and targeted medical therapy. However, warning signs such as intense pain, sudden visual loss, or infection demand prompt professional care.

---

References:

1. Mayo Clinic. Dry eye syndrome. Accessed March 2024. https://www.mayoclinic.org
2. American Academy of Ophthalmology. Dry eye disease. 2023. https://www.aao.org
3. American Journal of Clinical Nutrition. Omega‑3 fatty acids and dry eye: a systematic review. 2022;115(4):923‑935.
4. National Eye Institute (NEI). Dry Eye Disease. Updated 2023. https://www.nei.nih.gov
5. World Health Organization. Global report on vision 2022. WHO Press.